People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Biotechnology, Biotech, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tivic Health Systems, Inc. | — | Biotechnology | Series B | $36.2M | $62.4M | 2025 |
| CHD Bioscience, Inc. | — | Biotech | Series A | $18.7M | $3.3M | 2014 |
| Cytocom Inc. | — | Biotechnology | Series A | $8.3M | $167.3M | 2020 |
| Coeptis Therapeutics Inc. | — | Pharmaceuticals | Series A | $5.5M | $125.1M | 2021 |
Michael Handley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Handley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Mehalick | 1 | 5 |
| Alan Smith | 1 | 4 |
| William Nelson | 1 | 3 |
| Christine Sheehy | 1 | 3 |
| Roy Carver, Jr. | 1 | 2 |
| Jennifer Ernst | 1 | 2 |
| PETER ARONSTAM | 1 | 2 |
| Theodore Ziemann | 1 | 2 |
| Dean Zikria | 1 | 2 |
| Michael Litwack | 1 | 2 |
| Douglas Coder | 1 | 2 |
| Dennis Templar | 1 | 2 |
| Daniel Yerace | 1 | 2 |
| Cathy Sohn | 1 | 1 |
| Doug Coder | 1 | 1 |
| Loretta Mealy | 1 | 1 |
| Roy, Jr. Carver | 1 | 1 |
| Robert Kali | 1 | 1 |
| Ted Ziemann | 1 | 1 |
| Sheryle Bolton | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.